Clinical Trials on Papillomavirus Infection

Total 60944 results

National Cancer Institute (NCI)

Completed

Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191

Cervical Neoplasia | HPV Infections

Costa Rica
Kenya Medical Research Institute
Merck Sharp & Dohme LLC; University of Washington

Completed

Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys

HPV Infection | HPV Vaccine | HIV-1-infection

Kenya
Université de Sherbrooke

Active, not recruiting

Acceptability of HPV Self-sampling Among Canadian Women Aged 21 to 65 (CUTE-IPS)

Cervical Cancer Screening | HPV Infection

Canada
Deutsche Luft und Raumfahrt

Unknown

Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men

HIV Infections | Papillomavirus Infections | Anal Intraepithelial Neoplasia

Germany
Public Health England

Completed

Observational Follow up of Prior HPV Vaccinees (HPVfollowup)

Human Papillomavirus Virus

United Kingdom
The Institute of Molecular and Translational Medicine...
Cancer Research Czech Republic

Completed

HPVPro Study: Comparison of HPV Detection in Clinician-collected Cervical Swabs and Self-sampled Cervicovaginal Swabs (HPVPro)

Cervical Cancer | Human Papillomavirus Infection | Cervical Dysplasia

Czechia
Zhujiang Hospital
LanZhou University; The Second Hospital of Hebei Medical University; First Affiliated... and other collaborators

Recruiting

HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study

Uterine Cervical Neoplasms | Papillomavirus Infections | Sexual Transmitted Disease

China
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

"Lactobacillus Crispatus M247, LSIL and Microbiota"

ASC-US | LSIL | HPV Infection | Vaginal Flora Imbalance

Italy
Peking Union Medical College Hospital

Unknown

Persistent Cervical HPV Infection With Clearance and Vaginal Microbiota

HPV-Related Squamous Cell Carcinoma

China
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

Atypical Endometrial Hyperplasia | Human Papillomavirus Infection | Stage 0 Cervical Cancer AJCC v7

United States, Korea, Republic of, Japan
National University Hospital, Singapore

Unknown

Acceptability and Efficacy of Self-sampling for Cervical Cancer Screening: A Pilot Study

Cervical Cancer | Human Papillomavirus Infection | Cervical Dysplasia
Barretos Cancer Hospital
Merck Sharp & Dohme LLC

Completed

Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)

Infection | Human Papillomavirus
Hospital San Carlos, Madrid
Merck Sharp & Dohme LLC

Unknown

Retrospective Cohort Study of the Effectiveness of the Prophylactic Vaccine Against the Human Papilloma Virus in the Prevention of Recurrence in Women Who Have Received an Excisional Therapy by HSIL / CIN. (VENUS)

HPV Infection | HPV Vaccine | Cervix Lesion | Cervix, Dysplasia

Spain
Medical University of Vienna

Completed

On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection

Inflammatory Bowel Diseases | Psoriasis
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men

HIV Infection | Human Papillomavirus Infection | Anal Carcinoma

United States
GlaxoSmithKline

Completed

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Infections, Papillomavirus

United States, Canada
GlaxoSmithKline

Completed

Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)

Infections, Papillomavirus

China
GlaxoSmithKline

Completed

Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil

Infections, Papillomavirus

Brazil
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females

Infections, Papillomavirus
GlaxoSmithKline

Withdrawn

Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study

Infections, Papillomavirus
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

Infections, Papillomavirus

Panama, Mexico, Colombia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

Infections, Papillomavirus

Singapore, Hong Kong, France, Sweden
GlaxoSmithKline

Completed

The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Infections, Papillomavirus

Russian Federation, Singapore, Australia, Portugal
GlaxoSmithKline

Completed

Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine

Infections, Papillomavirus

Japan
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects

Infections, Papillomavirus

China
GlaxoSmithKline

Completed

Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women

Infections, Papillomavirus

India
GlaxoSmithKline

Completed

Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study

Infections, Papillomavirus

Brazil
GlaxoSmithKline

Completed

Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)

Infections, Papillomavirus

Belgium
GlaxoSmithKline

Completed

Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females

Infections, Papillomavirus
University of Georgia

Completed

Human Papilloma Virus (HPV) Vaccination Among Rural African American Primary Caregivers and Daughters

Human Papillomavirus

United States
The University of Texas Medical Branch, Galveston
Cancer Prevention Research Institute of Texas

Recruiting

Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)

HPV Infection | Human Papillomavirus | Immunization

United States
Fujian Maternity and Child Health Hospital

Recruiting

Prognostic Study of HPV Virus Integration in Women With HSIL

HPV Infection | Virus Integration | HSIL, High Grade Squamous Intraepithelial Lesions

China
GlaxoSmithKline

Completed

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

Infections, Papillomavirus | Papillomavirus Vaccines

Belgium
Louisiana State University Health Sciences Center...
Merck Sharp & Dohme LLC

Recruiting

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV (AGO-Gard)

Cervical Intraepithelial Neoplasia | Human Immunodeficiency Virus | Anal Intraepithelial Neoplasia | Papillomavirus Infection | Papillomavirus Vaccines | Serology | Oral Cavity Infection

United States
Klein Buendel, Inc.
National Cancer Institute (NCI); Indiana University; University of New Mexico

Completed

Web App Technology for Boys and Parents: Improving HPV Vaccine Uptake

HPV | Human Papillomavirus Virus

United States
National Cancer Institute (NCI)

Terminated

E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer

Papillomavirus Infections | Oropharyngeal Neoplasms

United States
Baylor College of Medicine
National Institute on Minority Health and Health Disparities (NIMHD)

Enrolling by invitation

Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS)

Cervical Cancer | Human Papillomavirus Infection

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University; Kaiser... and other collaborators

Completed

CATCH-UP Intervention in Increasing Cancer Screening and Prevention Care in Uninsured Patients at Community Health Centers

Breast Carcinoma | Cervical Carcinoma | Colorectal Carcinoma | Malignant Neoplasm | Human Papillomavirus Infection | Health Status Unknown

United States
GlaxoSmithKline

Completed

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.

Infections, Papillomavirus

Finland
GlaxoSmithKline

Completed

Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years

Infections, Papillomavirus

Netherlands
GlaxoSmithKline

Completed

Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.

Infections, Papillomavirus

Hong Kong
GlaxoSmithKline

Completed

Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years

Infections, Papillomavirus

Korea, Republic of
GlaxoSmithKline

Completed

Drug Use Investigation for Cervarix®

Infections, Papillomavirus
National Cancer Institute (NCI)

Withdrawn

A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer

Papillomavirus Infections | Oropharyngeal Neoplasms

United States
Milton S. Hershey Medical Center

Withdrawn

HPV Vaccine in Postpartum Women

HPV Infection
GlaxoSmithKline

Completed

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

Infections, Papillomavirus

Belgium, United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of California, Los Angeles; Merck... and other collaborators

Active, not recruiting

HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV (COVENANT)

HIV Infection | AIDS-Related Human Papillomavirus Infection | High Grade Cervical Squamous Intraepithelial Neoplasia

Uganda, Kenya, Zimbabwe, South Africa, Malawi
GlaxoSmithKline

Completed

Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18

Infections, Papillomavirus

Germany, Poland
GlaxoSmithKline

Completed

Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.

Infections, Papillomavirus

Taiwan, Spain, Germany, Colombia, France, Sweden, Australia, Korea, Republic of, Honduras, Czech Republic, Norway, Panama
GlaxoSmithKline

Completed

Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18

Infections, Papillomavirus

Finland, Russian Federation, Denmark, Greece, Netherlands, Estonia

Clinical Trials on Papillomavirus Infection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations